Asset profile
aleniglipron
Small molecule
Evidence outlook · registrational
Type 2 Diabetes: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2028-09.
NCT05762471: The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Because the primary safety endpoint has no posted results, whether it was met is unknown; the available design supports moderate evidence but not a strong positive conclusion.
Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.
Also in development:Obesity · Phase 3
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
September 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2028 (2)
September 2028 (2)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchWhat to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.